GlassScriptPhysician profile
Gabriel Alejandro Bolanos Guzman
NPI 1114403292
$2,517.16
in general payments reported to CMS, 2019-2025
22 companies · $899 in 2025
The $899 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $109 · 2022: $489 · 2023: $240 · 2024: $780 · 2025: $899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,672 · Education: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,671.84 |
| Education | $246.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $714.06 | 2023-2025 | Viberzi, Linzess, Skyrizi |
| Janssen Biotech, INC. | $674.71 | 2022-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $199.49 | 2022-2025 | Livdelzi |
| Takeda Pharmaceuticals U.S.A., INC. | $187.39 | 2022-2025 | Entyvio, Gattex |
| Braintree Laboratories, INC. | $147.40 | 2022 | |
| Phathom Pharmaceuticals, INC. | $92.19 | 2024-2025 | Voquezna |
| Mahana Therapeutics, INC. | $72.97 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.85 | 2022-2023 | Xifaxan |
| Madrigal Pharmaceuticals | $49.18 | 2025 | Rezdiffra |
| Janssen Pharmaceuticals, INC | $47.91 | 2021 | |
| Pfizer INC. | $41.38 | 2021-2024 | |
| Exact Sciences Corporation | $33.54 | 2024 | Cologuard Collection Kit |
| Intercept Pharmaceuticals, INC. | $32.65 | 2022-2023 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $25.06 | 2024 | Dupixent |
| Bayer Healthcare Pharmaceuticals INC. | $20.96 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $17.83 | 2025 | Ibsrela |
| Celltrion USA INC. | $16.47 | 2025 | Vegzelma |
| Merck Sharp & Dohme LLC | $16.26 | 2024 | Dificid |
| Aimmune Therapeutics, INC. | $16.07 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.23 | 2024 | Cyltezo |
| E.R. Squibb & Sons, L.L.C. | $14.81 | 2021 | |
| Olympus America INC. | $13.75 | 2025 | Single Use Repositionable Clip, Endoclot Phs |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Bolanos Guzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.